Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 19/20 | 0.57 |
| ▸ | DDB1 | Q16531 | 15/20 | 0.57 |
| ▸ | IKZF3 | Q9UKT9 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.57 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | TNF | P01375 | 2/20 | 0.48 |
| ▸ | IL1B | P01584 | 2/20 | 0.48 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.48 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.48 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29791273 | 1.00 | CRBN (0.57) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL23565390 | 0.84 | CRBN (0.44) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL23565384 | 0.82 | CRBN (0.50) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL23564796 | 0.82 | CRBN (0.46) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL23226068 | 0.82 | CRBN (0.62) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL26132842 | 0.81 | CRBN (0.42) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL31554606 | 0.81 | CRBN (0.61) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL20153862 | 0.81 | CRBN (0.61) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL4163462 | 0.81 | CRBN (0.61) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL24762106 | 0.81 | CRBN (0.61) | CRBNDDB1IKZF3ALDH1A1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230111853-A1 | COMPOUNDS MODULATING PROTEIN RECRUITMENT AND/OR DEGRADATION | ORIONIS BIOSCIENCES, INC. | 2023-04-13 | — | — | US | claimed |
| EP-4076464-A1 | COMPOUNDS MODULATING PROTEIN RECRUITMENT AND/OR DEGRADATION | Orionis Biosciences, Inc. (US) | 2022-10-26 | — | — | EP | claimed |
| CN-115038448-A | Compounds that modulate protein recruitment and/or degradation | 奥里尼斯生物科学股份有限公司 | 2022-09-09 | — | — | CN | claimed |
| WO-2021126973-A1 | COMPOUNDS MODULATING PROTEIN RECRUITMENT AND/OR DEGRADATION | ORIONIS BIOSCIENCES, INC. (US) | 2021-06-24 | — | — | WO | claimed |
| US-20230111853-A1 | COMPOUNDS MODULATING PROTEIN RECRUITMENT AND/OR DEGRADATION | ORIONIS BIOSCIENCES, INC. | 2023-04-13 | — | — | US | disclosed |
| US-20230111853-A1 | COMPOUNDS MODULATING PROTEIN RECRUITMENT AND/OR DEGRADATION | ORIONIS BIOSCIENCES, INC. | 2023-04-13 | — | — | US | disclosed |
| US-20230099031-A1 | BIFUNCTIONAL AGENTS FOR PROTEIN RECRUITMENT AND/OR DEGRADATION | ORIONIS BIOSCIENCES, INC. | 2023-03-30 | — | — | US | disclosed |
| CN-115348872-A | Bifunctional agents for protein recruitment and/or degradation | 奥里尼斯生物科学股份有限公司 | 2022-11-15 | — | — | CN | disclosed |
| EP-4076464-A1 | COMPOUNDS MODULATING PROTEIN RECRUITMENT AND/OR DEGRADATION | Orionis Biosciences, Inc. (US) | 2022-10-26 | — | — | EP | disclosed |
| EP-4076530-A1 | BIFUNCTIONAL AGENTS FOR PROTEIN RECRUITMENT AND/OR DEGRADATION | Orionis Biosciences, Inc. (US) | 2022-10-26 | — | — | EP | disclosed |
| CN-115038448-A | Compounds that modulate protein recruitment and/or degradation | 奥里尼斯生物科学股份有限公司 | 2022-09-09 | — | — | CN | disclosed |
| WO-2021126974-A1 | BIFUNCTIONAL AGENTS FOR PROTEIN RECRUITMENT AND/OR DEGRADATION | ORIONIS BIOSCIENCES, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021126973-A1 | COMPOUNDS MODULATING PROTEIN RECRUITMENT AND/OR DEGRADATION | ORIONIS BIOSCIENCES, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230111853-A1 | COMPOUNDS MODULATING PROTEIN RECRUITMENT AND/OR DEGRADATION | CRBN, STUB1, ADRM1 | CRBN 1/4885DDB1 171/4885IKZF3 463/4885 |
| US-20230099031-A1 | BIFUNCTIONAL AGENTS FOR PROTEIN RECRUITMENT AND/OR DEGRADATION | MDM2, SUMO2, MYCBP2 | CRBN 218/4885DDB1 65/4885IKZF3 1359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.